# REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Source: https://onco.cc/trials/nct05973773/  
OnCo record `nct05973773` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Zipalertinib in non-small-cell lung cancer, active and no longer recruiting.

## Summary

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumours) is a phase 3 interventional study registered as NCT05973773, led by Taiho Oncology, and active but no longer recruiting on the registry. Official title: Randomised, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations. Planned enrolment is 285 participants (actual). The study started in 2023-12-18 and primary completion is expected in 2027-05-27. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: REZILIENT3
- Tags: ctgov-ingest
- Registry id: NCT05973773
- Phase: 3
- Setting: Randomized, Controlled, Open-label, Phase 3, Global Multi - Center Trial to Assess the Efficacy and Safety of Zipalertinib Plus Chemotherapy Versus Chemotherapy Alone, in Patients With Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
- Sponsor: Taiho Oncology
- Enrolled: 285

## Sources

- ClinicalTrials.gov NCT05973773: https://clinicaltrials.gov/study/NCT05973773

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Zipalertinib](https://onco.cc/drugs/zipalertinib/)
- companies: [Taiho Oncology (Otsuka)](https://onco.cc/companies/taiho-oncology/)

---
JSON: https://onco.cc/api/v1/entities/nct05973773.json